The styblo model 20 years later: What holds true?

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 6, 2009, Pages 672-690

  Arnadottir, T ^a  

^a NONE   (Iceland)

Author keywords

Control; DOTS; Policy; Strategy; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE;

AFRICA; DISEASE SURVEILLANCE; DRUG RESISTANT TUBERCULOSIS; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; PANDEMIC; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; THEORETICAL MODEL; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; COOPERATIVE BEHAVIOR; DIRECTLY OBSERVED THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; INTERNATIONAL COOPERATION; MODELS, ORGANIZATIONAL; POLICY MAKING; TUBERCULOSIS; WORLD HEALTH;

EID: 67649230166     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Arnadottir T. Tuberculosis and public health: policy and principles in tuberculosis control. Paris, France: International Union Against Tuberculosis and Lung Disease, 2009.
2. Walsh J A, Warren K S. Selective primary health care. An interim strategy for disease control in developing countries. N Engl J Med 1979; 301: 967-974.
3. International Union Against Tuberculosis. Tanzania National Tuberculosis Programme. Bull Int Union Tuberc 1977; 52: 53-64.
4. Chen X, Zhao F, Duanmu H, et al. The DOTS strategy in China: results and lessons after 10 years. Bull World Health Organ 2002; 80: 430-436. (Pubitemid 34632818)
5. Jentgens H, Oberhoffer M, Rouillon A, Styblo K. Tuberculosis guide for high-prevalence countries. 1st ed. Aachen, Germany: Misereor, 1986.
6. Rouillon A. The Mutual Assistance Programme of the IUATLD. Development, contribution and significance. Bull Int Union Tuberc Lung Dis 1991; 66 (4): 159-172.
7. Chum H J, O'Brien R J, Chonde T M, Graf P, Rieder H L. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993. AIDS 1996; 10: 299-309.
8. Arnadottir T. Tuberculosis: trends and the twenty-first century. Scand J Infect Dis 2001; 33: 563-567.
9. Harries A D, Mbewe L N, Salaniponi F M L, et al. Tuberculosis programme changes and treatment outcomes in patients with smear-positive pulmonary tuberculosis in Blantyre, Malawi. Lancet 1996; 347: 807-809. (Pubitemid 26091647)
10. Shaw J B, Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status. Am Rev Tuberc 1954; 69: 724-732.
11. Elwood R K, Cook V J, Hernandez-Garduno E. Risk of tuberculosis in children from smear-negative source cases. Int J Tuberc Lung Dis 2005; 9: 49-55. (Pubitemid 40095109)
12. Marks S M, Taylor Z, Qualls N L, Shrestha-Kuwahara R J, Wilce M A, Nguyen C H. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 2000; 162: 2033-2038. (Pubitemid 32051659)
13. Espinal M A, Perés E N, Baéz J, et al. Infectiousness of Mycobacterium tuberculosis in HIV-1-infected patients with tuberculosis: a prospective study. Lancet 2000; 355: 275-280.
14. Tornee S, KaewKungwal J, Fungladda W, Silachamroon U, Akarasewi P, Sunakorn P. Risk factors for tuberculosis infection among household contacts in Bangkok, Thailand. Southeast Asian J Trop Med Public Health 2004; 35: 375-383. (Pubitemid 39248717)
15. Behr M A, Warren S A, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999; 353: 444-449.
16. Hernandez-Garduno E, Cook V, Kunimoto D, Elwood R K, Black W A, FitzGerald J M. Transmission of tuberculosis from smear-negative patients: a molecular epidemiology study. Thorax 2004; 59: 286-290. (Pubitemid 38496744)
17. Banerji D, Andersen S. A sociological study of awareness of symptoms among persons with pulmonary tuberculosis. Bull World Health Organ 1963; 29: 665-683.
18. Allan W G L, Girling D J, Fayers P M, Fox W. The symptoms of newly diagnosed pulmonary tuberculosis and patients' attitudes to the disease and to its treatment in Hong Kong. Tubercle 1979; 60: 211-223. (Pubitemid 10167305)
19. Johnson J L, Okwera A, Nsubuga P, et al. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Int J Tuberc Lung Dis 2000; 4: 1032-1040. (Pubitemid 30835302)
20. Nagpaul D R, Vishwanath M K, Dwarakanath G. A socioepidemiological study of out-patients attending a city tuberculosis clinic in India to judge the place of specialized centres in a tuberculosis control program. Bull World Health Organ 1970; 43: 17-34.
21. Nsanzumuhire H, Lukwago E W, Edwards E A, Stott H, Fox W, Sutherland I. A study of the use of community leaders in case-finding for pulmonary tuberculosis in the Machakos district in Kenya. Tubercle 1977; 58: 117-128. (Pubitemid 8183823)
22. Aluoch J A, Swai O B, Edwards E A, et al. Study of case-finding for pulmonary tuberculosis in outpatients complaining of a chronic cough at a district hospital in Kenya. Am Rev Respir Dis 1984; 129: 915-920. (Pubitemid 14111746)
23. Cassels A, Heineman E, LeClerq S. Tuberculosis case finding in Eastern Nepal. Tubercle 1982; 63: 175-185. (Pubitemid 12054730)
24. Santha T, Renu G, Frieden T R, et al. Are community surveys to detect tuberculosis in high prevalence areas useful? Result of a comparative study from Tiruvallur District, South India. Int J Tuberc Lung Dis 2003; 7: 258-265. (Pubitemid 36358767)
25. Tupasi T E, Radhakrishna S, Co V M, et al. Bacillary disease and health seeking behavior among Filipinos with symptoms of tuberculosis: implications for control. Int J Tuberc Lung Dis 2000; 4: 1126-1132. (Pubitemid 32046290)
26. Sherman L F, Fujiwara P I, Cook S V, Bazerman L B, Frieden T R. Patient and health care system delays in the diagnosis and treatment of tuberculosis. Int J Tuberc Lung Dis 1999; 3: 1088-1095.
27. Ngamvithayapong J, Yanai H, Winkvist A, Diwan V. Health seeking behaviour and diagnosis for pulmonary tuberculosis in an HIV-epidemic mountainous area of Thailand. Int J Tuberc Lung Dis 2001; 5: 1013-1020. (Pubitemid 33134751)
28. Rajeswari R, Chandrasekaran V, Suhadev M, Sivasubramanian S, Sudha G, Renu G. Factors associated with patient and health system delays in the diagnosis of tuberculosis in South India. Int J Tuberc Lung Dis 2002; 6: 789-795. (Pubitemid 34988049)
29. Golub J E, Bur S, Cronin W A, et al. Delayed tuberculosis diagnosis and tuberculosis transmission. Int J Tuberc Lung Dis 2006; 10: 24-30. (Pubitemid 43266273)
30. Harries A D, Kamenya A, Schoevers M A, et al. Case finding for pulmonary tuberculosis, Queen Elizabeth Central Hospital, Blantyre, Malawi. Int J Tuberc Lung Dis 1997; 1: 523-527. (Pubitemid 127509897)
31. Santha T, Garg R, Subramani R, et al. Comparison of cough of 2 and 3 weeks to improve detection of smear-positive tuberculosis cases among out-patients in India. Int J Tuberc Lung Dis 2005; 9: 61-68. (Pubitemid 40095111)
32. Tang S, Squire B S. What lessons can be drawn from tuberculosis (TB) control in China in the 1990s? An analysis from a health system perspective. Health Policy 2005; 72: 93-104. (Pubitemid 40349011)
33. Dembele S M, Ouédraogo H Z, Combary A I, Sondo B, Macq J, Dujardin B. Are patients who present spontaneously with PTB symptoms to the health services in Burkina Faso well managed? Int J Tuberc Lung Dis 2006; 10: 436-440.
34. Siddiqi K, Newell J N, Van der Stuyft P, et al. Improving sputum microscopy services for the diagnosis of tuberculosis in Peru and Bolivia. Int J Tuberc Lung Dis 2007; 11: 665-670. (Pubitemid 46868628)
35. Aneja K S, Gothi G D, Rupert Samuel G E. Controlled study of the effect of specific treatment on bacteriological status of 'suspect cases'. Indian J Tuberc 1979; 26: 50-57.
36. Hong Kong Chest Service/Tuberculosis Research Centre MBMRC. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months. Am Rev Respir Dis 1984; 130: 23-28.
37. Crofton J. The contribution of treatment to the prevention of tuberculosis. Bull Int Union Tuberc 1962; 32: 643-653.
38. Frimodt-Möller J. Changes in tuberculosis prevalence in a South Indian rural community following a tuberculosis control programme over a seven years' period (a preliminary report). Indian J Tuberc 1962; IX: 187-191.
39. Boulahbal F, Khaled S, Tazir M. The interest of follow-up of resistance of the tubercle bacillus in the evaluation of a programme. Bull Int Union Tuberc Lung Dis 1989; 64 (3): 23-25. (Pubitemid 20057635)
40. Grzybowski S, Enarson D A. The fate of cases of pulmonary tuberculosis under various treatment programmes. Bull Int Union Tuberc 1978; 53 (2): 70-75. (Pubitemid 9240283)
41. Kim S J, Bai G H, Hong Y P. Drug-resistant tuberculosis in Korea, 1994. Int J Tuberc Lung Dis 1997; 1: 302-308.
42. Crudu V, Arnadottir Th, Laticevschi D. Resistance to anti-tuberculosis drugs and practices in drug susceptibility testing in Moldova, 1995-1999. Int J Tuberc Lung Dis 2003; 7: 336-342. (Pubitemid 36433125)
43. Murray C J L, Salomon J A. Modeling the impact of global tuberculosis control strategies. Proc Natl Acad Sci USA 1998; 95: 13881-13886. (Pubitemid 28523067)
44. Murray C J L, Salomon J A. Expanding the WHO tuberculosis control strategy: rethinking the role of active case-finding. Int J Tuberc Lung Dis 1998; 2 (Suppl 1): S9-S15. (Pubitemid 28444986)
45. De Cock K M, Chaisson R E. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999; 3: 457-465. (Pubitemid 29260156)
46. Pronyk P M, Joshi B, Hargreaves J R, et al. Active case finding: understanding the burden of tuberculosis in rural South Africa. Int J Tuberc Lung Dis 2001; 5: 611-618. (Pubitemid 32652150)
47. Wan L, Cheng S, Chin D P. A new disease reporting system increases TB case detection in China. Bull World Health Organ 2007; 85: 401. (Pubitemid 46718375)
48. Baily G V J, Savic D, Gothi G D, Naidu V B, Nair S S. Potential yield of pulmonary tuberculosis cases by direct microscopy of sputum in a district of South India. Bull World Health Organ 1967; 37: 875-892.
49. Bastos L G V, Fonseca L S, Mello F C Q, Ruffino-Netto A, Golub J L, Conde M B. Prevalence of pulmonary tuberculosis among respiratory symptomatic subjects in an out-patient primary health unit. Int J Tuberc Lung Dis 2007; 11: 156-160. (Pubitemid 46219278)
50. Andrews R H, Radhakrishna S. A comparison of two methods of sputum collection in the diagnosis of pulmonary tuberculosis. Tubercle 1959; 40: 155-162.
51. Mase S R, Ramsay A, Ng V, et al. Yield of serial sputum specimen examination in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2007; 11: 485-495. (Pubitemid 46732633)
52. Van Deun A, Hamid Salim H, Coorman E, et al. Optimal tuberculosis case detection by direct sputum smear microscopy: how much better is more? Int J Tuberc Lung Dis 2002; 6: 222-230. (Pubitemid 34270100)
53. Alisjahbana B, ven Crevel R, Danusantoso H, et al. Better patient instruction for sputum sampling can improve microscopic tuberculosis diagnosis. Int J Tuberc Lung Dis 2005; 9: 814-817.
54. Khan M S, Dar O, Sismanidis C, Shah K, Godfrey-Faussett P. Improvement of tuberculosis case detection and reduction of discrepancies between men and women by simple sputum-submission instructions: a pragmatic randomised controlled trial. Lancet 2007; 369: 1955-1960. (Pubitemid 46874579)
55. Harries A D, Nyirenda T E, Banerjee A, Mundy C, Salaniponi F M. District sputum smear microscopy services in Malawi. Int J Tuberc Lung Dis 1998; 2: 914-918. (Pubitemid 28539475)
56. Brudney K, Dobkin J. A tale of two cities: tuberculosis control in Nicaragua and New York City. Sem Respir Infect 1991; 6: 261-272.
57. Cambanis A, Ramsay A, Wirkom V, Tata E, Cuevas L E. Investing time in microscopy: an opportunity to optimise smear-based case detection of tuberculosis. Int J Tuberc Lung Dis 2007; 11: 40-45. (Pubitemid 46101844)
58. Tuberculosis Division International Union Against Tuberculosis and Lung Disease. Tuberculosis bacteriology - priorities and indications in high prevalence countries: position of the technical staff of the Tuberculosis Division of the International Union Against Tuberculosis and Lung Disease. Int J Tuberc Lung Dis 2005; 9: 355-361. (Pubitemid 40528435)
59. Narain R, Nair S S, Naganna K, Chandrasekhar P, Ramanatha G, Lal P. Problems defining a 'case' of pulmonary tuberculosis in prevalence surveys. Bull World Health Organ 1968; 39: 701-729.
60. Levy H, Feldman C, Sacho H, van der Meulen H, Kallenbach J, Koornhof H. A reevaluation of sputum microscopy and culture in the diagnosis of pulmonary tuberculosis. Chest 1989; 95: 1193-1197. (Pubitemid 19160138)
61. Van Deun A, Hamid Salim A, Coorman E, et al. Scanty AFB smears: what's in a name? Int J Tuberc Lung Dis 2004; 8: 816-823.
62. Larbaoui D, Chaulet P, Grosset J, Abderrahim K, Ait-Mesbah H. The efficiency of methods of diagnosing pulmonary tuberculosis: an investigation in a chest clinic in Algiers. Tubercle 1970; 51: 403-411.
63. Aluoch J A, Swai O B, Edwards E A, et al. Studies of case-finding for pulmonary tuberculosis in outpatients at 4 district hospitals in Kenya. Tubercle 1985; 66: 237-249. (Pubitemid 16203092)
64. Siddiqi K, Lambert M-L, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis 2003; 3: 288-296. (Pubitemid 36565881)
65. Lambert M-L, Sugulle H, Seyoum D, et al. How can detection of infectious tuberculosis be improved? Experience in the Somali region of Ethiopia. Int J Tuberc Lung Dis 2003; 7: 485-488. (Pubitemid 36565420)
66. East African/British Medical Research Councils. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Tubercle 1980; 61: 59-69.
67. Aneja K S, Rupert Samuel G E. Organizational effort in a clinical trial and its relevance to applicability of short-course chemotherapy in national tuberculosis programme. Indian J Tuberc 1982; 29: 19-28.
68. Van Deun A, Aung K J M, Hamid Salim M A, et al. Extension of the intensive phase reduces unfavourable outcomes with the 8-month thioacetazone regimen. Int J Tuberc Lung Dis 2006; 10: 1255-1261. (Pubitemid 44713480)
69. Rich M L, Socci A R, Mitnick C D, et al. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis 2006; 10: 290-296.
70. Van Deun A, Hamid Salim A, Rigouts L, Rahman M, Fissette K, Portaels F. Evaluation of tuberculosis control by periodic or routine susceptibility testing in previously treated cases. Int J Tuberc Lung Dis 2001; 5: 329-338. (Pubitemid 32397583)
71. Perriens J H, Colebunders R L, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with 'standard' chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991; 144: 750-755.
72. Albert R K, Sbarbaro J A, Hudson L D, Iseman M. High-dose ethambutol: its role in intermittent chemotherapy. A six-year study. Am Rev Respir Dis 1976; 114: 699-704.
73. Chum H J, Ilmolelian G, Rieder H L, et al. Impact of the change from an injectable to a fully oral regimen on patient adherence to ambulatory tuberculosis treatment in Dar es Salaam, Tanzania. Tubercle Lung Dis 1995; 76: 286-289.
74. Rabarijaona L, Boisier P, Ratsirahonana O, et al. Replacement of streptomycin by ethambutol in the intensive phase of tuberculosis treatment: no effect on compliance. Int J Tuberc Lung Dis 1999; 3: 42-46. (Pubitemid 29136559)
75. Johansson E, Diwan V K, Huong N D, Ahlberg B M. Staff and patient attitudes to tuberculosis and compliance with treatment: an exploratory study in a district in Vietnam. Tubercle Lung Dis 1996; 77: 178-183. (Pubitemid 26139152)
76. Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991; 377: 627-630.
77. Jindani A, Nunn A J, Enarson D A. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-1251. (Pubitemid 39311345)
78. World Health Organization. Treatment of tuberculosis. Guidelines for national programmes. 3rd ed. Geneva, Switzerland: WHO, 2003.
79. Becx-Bleumink M, Djamaluddin S, Loprang F, de Soldenhoff R, Wibowo H, Aryono M. High cure rates in smear-positive tuberculosis patients using ambulatory treatment with once-weekly supervision during the intensive phase in Sulawesi, Republic of Indonesia. Int J Tuberc Lung Dis 1999; 3: 1066-1072.
80. Suryanto A A, van den Broek J, Hatta M, de Soldenhoff R, van der Werf M J. Is there an increased risk of TB relapse in patients treated with fixed-dose combination drugs in Indonesia? Int J Tuberc Lung Dis 2008; 12: 174-179.
81. Chang K C, Leung C C, Yew W W, Chan S L, Tam C M. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 1153-1158. (Pubitemid 44772087)
82. East and Central African/British Medical Research Council Fifth Collaborative Study. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tubercle 1986; 67: 5-15.
83. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430. (Pubitemid 16126276)
84. Hong Kong Chest Service/British Medical Research Council. A study in Hong Kong to evaluate the role of pretreatment susceptibility tests in the selection of regimens of chemotherapy for pulmonary tuberculosis - second report. Tubercle 1974; 55: 169-192.
85. Chonde T M. The role of bacteriological services in the National Tuberculosis and Leprosy Programme in Tanzania. Bull Int Union Tuberc Lung Dis 1989; 64 (3): 37-39. (Pubitemid 20057640)
86. Urbanczik R, Shrestha B, Maharjan B, Neher A, Feldmann K. Appropriateness of using two instead of a single sputum specimen for monitoring treatment of pulmonary tuberculosis [Correspondence]. Int J Tuberc Lung Dis 2004; 8: 1510. (Pubitemid 40070260)
87. Enarson D A, Jindani A, Kuaban C, et al. Appropriateness of extending the intensive phase of treatment based on smear results. Int J Tuberc Lung Dis 2004; 8: 114-115. (Pubitemid 38120714)
88. Jindani A, Aber V R, Edwards E A, Mitchison D A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-949. (Pubitemid 10118376)
89. Baily G V J, Rupert Samuel G E, Nagpaul D R. A concurrent comparison of an unsupervised self-administered daily regimen and a fully supervised twice weekly-regimen of chemotherapy in a routine out-patient treatment programme. Indian J Tuberc 1974; 21: 152-167.
90. Horwits O, Palmer C E. Epidemiological basis of tuberculosis eradication. 2. Dynamics of tuberculosis morbidity and mortality. Bull World Health Organ 1964; 30: 609-621.
91. Dick J, Van-der-Walt H, Hoogendoorn L, Tobias B. Development of a health education booklet to enhance adherence to tuberculosis treatment. Tubercle Lung Dis 1996; 77: 173-177. (Pubitemid 26139151)
92. Lonnroth K, Tran T U, Thuong L M, Quy H T, Diwan V. Can I afford free treatment? Perceived consequences of health care provider choices among people with tuberculosis in Ho Chi Minh City, Vietnam. Soc Sci Med 2001; 52: 935-948. (Pubitemid 32012453)
93. Volmink J, Garner P. Directly observed therapy for treating tuberculosis [Review]. Cochrane Database Syst Rev 2007; 4: CD003343. (Pubitemid 351805205)
94. Weis S E, Slocum P C, Blais F X, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179-1184. (Pubitemid 24121986)
95. Weis S E, Foresman B, Matty K J, et al. Treatment costs of directly observed therapy and traditional therapy for Mycobacterium tuberculosis: a comparative analysis. Int J Tuberc Lung Dis 1999; 3: 976-984.
96. Bayer R, Dubler N N, Landesman S. The dual epidemics of tuberculosis and AIDS: ethical and policy issues in screening and treatment. Am J Public Health 1993; 83: 649-654. (Pubitemid 23142988)
97. Bayer R, Stayton C, Desvarieux M, Healton C, Landesman S, Tsai W-Y. Directly observed therapy and treatment completion for tuberculosis in the United States: is universal supervised therapy necessary? Am J Public Health 1998; 88: 1052-1058.
98. Balasubramanian V N, Oommen K, Samuel R. DOT or not? Direct observation of anti-tuberculosis treatment and patient outcomes, Kerala State, India. Int J Tuberc Lung Dis 2000; 4: 409-413. (Pubitemid 30256842)
99. Hane F, Thiam S, Fall A S, et al. Identifying barriers to effective tuberculosis control in Senegal: an anthropological approach. Int J Tuberc Lung Dis 2007; 11: 539-543. (Pubitemid 46732641)
100. Pungrassami P, Johnsen S P, Chongsuvivatwong V, Olsen J, Sorensen H T. Practice of directly observed treatment (DOT) for tuberculosis in southern Thailand: comparison between different types of DOT observers. Int J Tuberc Lung Dis 2002; 6: 389-395. (Pubitemid 34492162)
101. Bastian I, Rigouts L, Van Deun A, Portaels F. Directly observed treatment, short course strategy and multidrug-resistant tuberculosis: are any modifications required? Bull World Health Organ 2000; 78: 238-251.
102. Crofton J. Tuberculosis undefeated. Ir J Med Sci 1985; 154: 45-52.
103. Binkin N J, Vernon A A, Simone P M, et al. Tuberculosis prevention and control activities in the United States: an overview of the organization of tuberculosis services. Int J Tuberc Lung Dis 1999; 3: 663-674. (Pubitemid 29378466)
104. Munsiff S S, Ahuja S D, King L, et al. Ensuring accountability: the contribution of the cohort review method to tuberculosis control in New York City. Int J Tuberc Lung Dis 2006; 10: 1133-1139. (Pubitemid 44519352)
105. Rieder H L, Arnadottir Th, Trébucq A, Enarson D A. Tuberculosis treatment: dangerous regimens? Int J Tuberc Lung Dis 2001; 5: 1-3.
106. Atun R A, Samyshkin Y A, Drobniewski F, Kuznetsov S I, Fedorin I M, Coker R J. Social factors influencing hospital utilisation by tuberculosis patients in the Russian Federation: analysis of routinely collected data. Int J Tuberc Lung Dis 2005; 9: 1140-1146. (Pubitemid 41433804)
107. Farmer P, Kim J Y. Community based approaches to the control of multidrug resistant tuberculosis: introducing 'DOTS-plus'. BMJ 1998; 317: 671-674.
108. Farmer P, Bayona J, Becerra M, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 1998; 2: 869-876. (Pubitemid 28539468)
109. Bonnet M, Sizaire V, Kebede Y, et al. Does one size fit all? Drug resistance and standard treatments: results of six tuberculosis programmes in former Soviet countries. Int J Tuberc Lung Dis 2005; 9: 1147-1154. (Pubitemid 41433805)
110. Dosso M, Bonard D, Msellati P, et al. Primary resistance to anti-tuberculosis drugs: a national survey conducted in Cote d'Ivoire in 1995-1996. Int J Tuberc Lung Dis 1999; 3: 805-809.
111. Yoshiyama T, Yanai H, Rhiengtong D, et al. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int J Tuberc Lung Dis 2004; 8: 31-38. (Pubitemid 38120703)
112. Quy H T, Buu T N, Cobelens F G, Lan N T N, Lambregts C S B, Borgdorff M W. Drug resistance among smear-positive tuberculosis patients in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2006; 10: 160-166. (Pubitemid 43275539)
113. Sanders M, Van Deun A, Ntakirutimana D, et al. Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey. Int J Tuberc Lung Dis 2006; 10: 178-183.
114. Kenyon T A, Mwasekaga M J, Huebner R, Rumisha D, Binkin N, Maganu E. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis 1999; 3: 4-11. (Pubitemid 29136554)
115. China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet 2004; 364: 417-422.
116. Heller R F, Gemmell I, Edwards R, Buchan I, Awasthi S, Volmink J A. Prioritising between direct observation of therapy and case-finding interventions for tuberculosis: use of population impact measures. BMC Med 2006; 4: 35.
117. Dye C, Watt C J, Bleed D M, Williams B G. What is the limit of case detection under the DOTS strategy for tuberculosis control? Tuberculosis 2003; 83: 35-43.
118. Porter J, Lee K, Ogden J. The globalisation of DOTS: tuberculosis as a global emergency. In: Lee K, Buse K, Fustukian S, eds. Health policy in a globalising world. Cambridge, UK: Cambridge University Press, 2002: pp 180-194.
119. Singh V, Jaiswal A, Porter J D H, et al. TB control, poverty and vulnerability in Delhi, India. Trop Med Intern Health 2002; 7: 693-700. (Pubitemid 35300702)
120. Styblo K. Impact of HIV infection on the tuberculosis problem worldwide. Kekkaku 1990; 65: 429-438. (Pubitemid 20325007)
121. Guwatudde D, Debanne S M, Diaz M, King C, Whalen C C. A re-examination of the potential impact of preventive therapy on the public health problem of tuberculosis in contemporary sub-Saharan Africa. Prev Med 2004; 39: 1036-1046. (Pubitemid 39314473)
122. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064. (Pubitemid 34680968)
123. Munthali L, Mwaungulu J N, Munthali K, Bowie C, Crampin A C. Using tuberculosis suspects to identify patients eligible for antiretroviral treatment. Int J Tuberc Lung Dis 2006; 10: 199-202. (Pubitemid 43275546)